Optimization of the rifampin dosage to improve the therapeutic efficacy in tuberculosis treatment using a murine model

American Journal of Respiratory and Critical Care Medicine

Volumn 187, Issue 10, 2013, Pages 1127-1134

  De Steenwinkel, Jurriaan E M ^a   Aarnoutse, Rob E ^b   De Knegt, Gerjo J ^a   Ten Kate, Marian T ^a   Teulen, Marga ^b   Verbrugh, Henri A ^a   Boeree, Martin J ^b   Van Soolingen, Dick ^b,c   Bakker Woudenberg, Irma A J M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

Murine tuberculosis model; Pharmacokinetics; Rifampin; Treatment improvement

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREATININE; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GENOTYPE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; PROCESS OPTIMIZATION; RELAPSE; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; UREA NITROGEN BLOOD LEVEL;

ANIMALS; ANTIBIOTICS, ANTITUBERCULAR; AREA UNDER CURVE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; MAXIMUM TOLERATED DOSE; MICE; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS; RIFAMPIN; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 84877913951     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201207-1210OC     Document Type: Article

References (35)

1. van den Boogaard J, Boeree MJ, Kibiki GS, Aarnoutse RE. The complexity of the adherence-response relationship in tuberculosis treatment: why are we still in the dark and howcan we get out? Trop Med Int Health 2011;16:693-698.
2. Ginsberg AM. Drugs in development for tuberculosis. Drugs 2010;70:2201-2214.
3. van den Boogaard J, Kibiki GS, Kisanga ER, Boeree MJ, Aarnoutse RE. New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development. Antimicrob Agents Chemother 2009;53:849-862.
4. van Ingen J, Aarnoutse RE, Donald PR, Diacon AH, Dawson R, Plemper van Balen G, Gillespie SH, Boeree MJ. Why do we use 600 mg of rifampicin in tuberculosis treatment? Clin Infect Dis 2011;52:e194-e199.
5. Verbist L. Rifampicin activity "in vitro" and in established tuberculosis in mice. Acta Tuberc Pneumol Belg 1969;60:397-412.
6. Steingart KR, Jotblad S, Robsky K, Deck D, Hopewell PC, Huang D, Nahid P. Higher-dose rifampin for the treatment of pulmonary tuberculosis: a systematic review. Int J Tuberc Lung Dis 2011;15:305-316.
7. Jayaram R, Gaonkar S, Kaur P, Suresh BL, Mahesh BN, Jayashree R, Nandi V, Bharat S, Shandil RK, Kantharaj E, et al. Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother 2003;47:2118-2124. (Pubitemid 36753560)
8. Diacon AH, Patientia RF, Venter A, van Helden PD, Smith PJ, McIlleron H, Maritz JS, Donald PR. Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears. Antimicrob Agents Chemother 2007;51:2994-2996. (Pubitemid 47206244)
9. Ruslami R, Nijland HM, Alisjahbana B, Parwati I, van Crevel R, Aarnoutse RE. Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients. Antimicrob Agents Chemother 2007;51:2546-2551. (Pubitemid 47047335)
10. Ruslami R, Ganiem A, Dian S, Apriani L, Achmad T, van der Ven A, Borm G, Aarnoutse R, van Crevel R. Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial. Lancet Infect Dis 2013;13:27-35.
11. Boeree M, Diacon A, Dawson R, du Bois J, Narunsky K, Venter A, Gillespie S, McHugh T, Hoelscher M, Heinrich N, et al. What is the right dose of rifampin? An interim report [abstract]. Presented at the 5th International Workshop on Clinical Pharmacology of TB Drugs. September 8, 2012. San Francisco, CA.
12. Rosenthal IM, Tasneen R, Peloquin CA, Zhang M, Almeida D, Mdluli KE, Karakousis PC, Grosset JH, Nuermberger EL. Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis. Antimicrob Agents Chemother 2012;56:4331-4340.
13. Goutelle S, Bourguignon L, Maire PH, Van Guilder M, Conte JE Jr, Jelliffe RW. Population modeling and Monte Carlo simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of rifampin in lungs. Antimicrob Agents Chemother 2009;53:2974-2981.
14. Gumbo T, Louie A, Deziel MR, Liu W, Parsons LM, Salfinger M, Drusano GL. Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob Agents Chemother 2007;51:3781-3788. (Pubitemid 350057771)
15. Parwati I, van Crevel R, van Soolingen D. Possible underlying mechanisms for successful emergence of the Mycobacterium tuberculosis Beijing genotype strains. Lancet Infect Dis 2010;10:103-111.
16. Parwati I, Alisjahbana B, Apriani L, Soetikno RD, Ottenhoff TH, van der Zanden AG, van der Meer J, van Soolingen D, van Crevel R. Mycobacterium tuberculosis Beijing genotype is an independent risk factor for tuberculosis treatment failure in Indonesia. J Infect Dis 2010;201:553-557.
17. de Steenwinkel JE, de Knegt GJ, Ten Kate MT, van Belkum A, Verbrugh HA, Hernandez-Pando R, van Soolingen D, Bakker-Woudenberg IA. Immunological parameters to define infection progression and therapy response in a well-defined tuberculosis model in mice. Int J Immunopathol Pharmacol 2009;22:723-734.
18. de Steenwinkel JE, ten Kate MT, de Knegt GJ, Verbrugh HA, Aarnoutse RE, Boeree M, den Bakker MA, van Soolingen D, Bakker- Woudenberg IA. Consequences of non-compliance on therapy efficacy and emergence of resistance in murine tuberculosis caused by the Beijing genotype. Antimicrob Agents Chemother 2012;56:4937-4944.
19. de Knegt G, Aarnoutse R, ten Kate M, Teulen M, Boeree M, van Soolingen D, Bakker-Woudenberg I, de Steenwinkel J. Increasing rifampicin dosage in the treatment of murine tuberculosis allows reduction of therapy duration. [abstract]. Presented at the 52nd ICAAC Interscience Conference on Antimicrobial Agents and Chemotherapy. September 10, 2012. San Francisco, CA.
20. de Knegt G, Aarnoutse R, ten Kate M, Teulen M, Boeree M, van Soolingen D, Bakker-Woudenberg I, de Steenwinkel J. Optimization of the rifampicin dosage to improve therapeutic efficacy in tuberculosis treatment, using a murine model. [abstract]. Presented at the 5th International Workshop on Clinical Pharmacology of TB Drugs. September 8, 2012. San Francisco, CA.
21. de Steenwinkel JE, ten Kate MT, de Knegt GJ, Kremer K, Aarnoutse RE, Boeree MJ, Verbrugh HA, van Soolingen D, Bakker-Woudenberg IA. Drug susceptibility of Mycobacterium tuberculosis Beijing genotype and association with MDR TB. Emerg Infect Dis 2012;18:660-663.
22. Woods GL, Brill MR, Brown-Elliot BA, Desmond EP, Hall GS, Killian SB, Pfyffer GE, Ridderhof JC, Witebsky FG. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes. Approved standard, second edition. Wayne, PA: Clinical and Laboratory Standards Institute; 2011. M24-A2, volume 26:1-61.
23. Aarnoutse RE, Mooren FW, Nijland H, Apriyani L, Wieringa F, van Crevel R, Ruslami R. Evaluation of protein-unbound, active concentrations of rifampicin in Indonesian tuberculosis patients. Presented at the Fourth International Workshop on Clinical Pharmacology of TB Drugs. September 16, 2011. Chicago, IL.
24. Tostmann A, Mtabho CM, Semvua HH, van den Boogaard J, Boeree MJ, Kibiki GS, Aarnoutse RE. Pharmacokinetics of first line tuberculosis drugs in Tanzanian tuberculosis patients. Antimicrob Agents Chemother (In press).
25. Rosenthal IM, Zhang M, Williams KN, Peloquin CA, Tyagi S, Vernon AA, Bishai WR, Chaisson RE, Grosset JH, Nuermberger EL. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med 2007;4:e344.
26. Dooley KE, Bliven-Sizemore EE, Weiner M, Lu Y, Nuermberger EL, Hubbard WC, Fuchs EJ, Melia MT, Burman WJ, Dorman SE. Safety and pharmacokinetics of escalating daily doses of the antituberculosis drug rifapentine in healthy volunteers. Clin Pharmacol Ther 2012;91:881-888.
27. Buu TN, Huyen MN, Lan NT, Quy HT, Hen NV, Zignol M, Borgdorff MW, Cobelens FG, van Soolingen D. The Beijing genotype is associated with young age and multidrug-resistant tuberculosis in rural Vietnam. Int J Tuberc Lung Dis 2009;13:900-906.
28. de Steenwinkel JE, de Knegt GJ, ten Kate MT, van Belkum A, Verbrugh HA, Kremer K, van Soolingen D, Bakker-Woudenberg IA. Time-kill kinetics of anti-tuberculosis drugs, and emergence of resistance, in relation to metabolic activity of Mycobacterium tuberculosis. J Antimicrob Chemother 2010;65:2582-2589.
29. Acocella G. Clinical pharmacokinetics of rifampicin. Clin Pharmacokinet 1978;3:108-127.
30. Kenny MT, Strates B. Metabolism and pharmacokinetics of the antibiotic rifampin. Drug Metab Rev 1981;12:159-218. (Pubitemid 12208844)
31. Lyons MA, Reisfeld B, Yang RS, Lenaerts AJ. A physiologically based pharmacokinetic model of rifampin in mice. Antimicrob Agents Chemother 2013;57:1763-1771.
32. Dutta NK, Alsultan A, Peloquin CA, Karakousis PC. Preliminary pharmacokinetic study of repeated doses of rifampin and rifapentine in guinea pigs. Antimicrob Agents Chemother 2013;57:1535-1537.
33. Rastogi N, Goh KS, Berchel M, Bryskier A. Activity of rifapentine and its metabolite 25-o-desacetylrifapentine compared with rifampicin and rifabutin against Mycobacterium tuberculosis, Mycobacterium africanum, Mycobacterium bovis and M. Bovis BCG. J Antimicrob Chemother 2000;46:565-570.
34. De Groote MA, Gruppo V, Woolhiser LK, Orme IM, Gilliland JC, Lenaerts AJ. Importance of confirming in vivo efficacy data of novel antibacterial drug regimens against various strains of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2012;56:731-738.
35. Grosset J. The sterilizing value of rifampicin and pyrazinamide in experimental short-course chemotherapy. Bull Int Union Tuberc 1978;53:5-12. (Pubitemid 9243249)